Ackerman Capital Advisors LLC Invests $222,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Ackerman Capital Advisors LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, HoldingsChannel reports. The institutional investor purchased 3,500 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

Several other hedge funds have also modified their holdings of GILD. Nuveen Asset Management LLC lifted its holdings in shares of Gilead Sciences by 1,208.1% during the second quarter. Nuveen Asset Management LLC now owns 9,847,359 shares of the biopharmaceutical company’s stock worth $665,288,000 after buying an additional 9,094,586 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Gilead Sciences by 56.9% during the second quarter. Renaissance Technologies LLC now owns 12,740,248 shares of the biopharmaceutical company’s stock worth $860,731,000 after buying an additional 4,620,000 shares during the last quarter. Invesco Ltd. lifted its holdings in shares of Gilead Sciences by 17.5% during the second quarter. Invesco Ltd. now owns 22,975,310 shares of the biopharmaceutical company’s stock worth $1,552,213,000 after buying an additional 3,418,193 shares during the last quarter. Marshall Wace North America L.P. lifted its holdings in shares of Gilead Sciences by 298.3% during the second quarter. Marshall Wace North America L.P. now owns 3,418,196 shares of the biopharmaceutical company’s stock worth $230,934,000 after buying an additional 2,559,972 shares during the last quarter. Finally, Miller Howard Investments Inc. NY acquired a new position in shares of Gilead Sciences during the second quarter worth approximately $93,386,000. Institutional investors own 79.57% of the company’s stock.

Shares of NASDAQ GILD traded up $0.29 during trading hours on Wednesday, reaching $61.98. The stock had a trading volume of 2,326,597 shares, compared to its average volume of 6,700,060. The business’s fifty day moving average is $64.15 and its two-hundred day moving average is $65.36. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.76 and a quick ratio of 3.67. The company has a market cap of $78.76 billion, a price-to-earnings ratio of 10.08, a PEG ratio of 2.97 and a beta of 1.10. Gilead Sciences, Inc. has a twelve month low of $60.32 and a twelve month high of $77.39.



Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating analysts’ consensus estimates of $1.68 by $0.14. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The business had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.54 billion. During the same period in the prior year, the company posted $1.91 earnings per share. Gilead Sciences’s revenue was down 2.8% on a year-over-year basis. Sell-side analysts forecast that Gilead Sciences, Inc. will post 6.66 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Shareholders of record on Friday, September 13th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, September 12th. This represents a $2.52 annualized dividend and a yield of 4.07%. Gilead Sciences’s dividend payout ratio is currently 40.98%.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 7,200 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total transaction of $468,504.00. Following the completion of the transaction, the executive vice president now directly owns 34,398 shares in the company, valued at $2,238,277.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Brett A. Pletcher sold 608 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $64.35, for a total value of $39,124.80. Following the transaction, the executive vice president now owns 27,198 shares of the company’s stock, valued at $1,750,191.30. The disclosure for this sale can be found here. Insiders have sold 12,716 shares of company stock valued at $821,299 over the last quarter. Corporate insiders own 0.20% of the company’s stock.

GILD has been the subject of a number of research analyst reports. BidaskClub lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Friday, September 27th. Morgan Stanley set a $82.00 target price on Gilead Sciences and gave the company a “hold” rating in a research note on Monday, July 15th. Wells Fargo & Co upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their target price for the company from $68.00 to $88.00 in a research note on Monday, July 15th. Citigroup set a $78.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, July 31st. Finally, Raymond James set a $85.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Friday, August 23rd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and a consensus price target of $82.24.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Read More: How Do Tariffs Affect Trade Balances?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.